Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 58, Issue 4, 2004, Pages 364-368

  Chaichan, Warawat ^a  

^a Nakhonsawan Rajanakarindra Psychiatric Hospital   (Thailand)

Author keywords

Brief psychiatric rating scale; Fluvoxamine; Olanzapine; Schizophrenia

Indexed keywords

DIAZEPAM; FLUVOXAMINE; HALOPERIDOL; OLANZAPINE; PLACEBO; TRIHEXYPHENIDYL;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EMOTIONAL DISORDER; FEMALE; HUMAN; LASSITUDE; MALE; MEMORY DISORDER; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; THAILAND; UNIVERSITY HOSPITAL; WEIGHT GAIN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; THAILAND; TREATMENT OUTCOME;

EID: 4243182676     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2004.01269.x     Document Type: Article

References (17)

1. Kane JM. Schizophrenia. N. Eng. J. Med. 1996; 334: 34-41.
2. Sharif ZA. Common treatment goals of antipsychotics: acute treatment. J. Clin. Psychiatry 1998; 59 (Suppl. 19): 5-8.
3. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997; 17: 407-418.
4. Tollefson GD, Beasley CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997; 154: 457-465.
5. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry Monograph 1997; 15 (2): 24-26.
6. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psychopharmacol. 1997; 17: 472-477.
7. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br. J. Psychiatry 1999; 174 (Suppl. 37): 30-35.
8. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin. Neuropharmacol. 2003; 26: 58-61.
9. Ereshefsky L. Pharmacokinetics and drug interaction: update for new antipsychotics. J. Clin. Psychiatry 1996; 57 (Suppl. 11): 12-25.
10. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur. J. Clin. Pharmacol. 1998; 54: 639-643.
11. Ring BJ, Catlow J, Lindsay TJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pyarmacol. Exp. Ther. 1996; 276: 658-666.
12. McEvoy JP, Weiden PJ, Smith TE et al. Treatment of schizophrenia. J. Clin. Psychiatry 1996; 57 (Suppl. 12B): 15-58.
13. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 1998; 18: 208-211.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC, 1994.
15. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Report 1962; 10: 799-812.
16. Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. Acta Psychiatr. Scand. 1987; 76 (Suppl. 334): 1-100.
17. Hiemke C, Peled A, Jabarin M et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J. Clin. Psychopharmacol. 2002; 22: 502-506.